过氧化物酶体增殖物激活受体5是卵巢癌的负性生存预测指标。
Peroxiredoxin-5 is a negative survival predictor in ovarian cancer.
作者信息
Sienko Jacek, Gaj Paweł, Czajkowski Krzysztof, Nowis Dominika
机构信息
2nd Department of Obstetrics and Gynecology, Medical University of Warsaw, Poland.
Laboratory of Human Cancer Genetics, Center of New Technologies, University of Warsaw, Poland.
出版信息
Ginekol Pol. 2019;90(1):1-6. doi: 10.5603/GP.2019.0001.
OBJECTIVES
Peroxiredoxins (PRDXs) constitute a family of antioxidant enzymes which are also involved in the process of carcinogenesis. They are composed of six identified isoforms (PRDX-1-6) and are supposed to play different roles in tumor progression, depending on type of cancer and member of the PRDX family. The aim of the study was to assess the prog- nostic value of PRDXs in ovarian cancer.
MATERIAL AND METHODS
a dataset of patients with ovarian cancer from The Cancer Genome Atlas was analyzed. Expression of PRDX-1 to 6 mRNA was evaluated in 260 samples. The prognostic value of PRDXs was assessed using the Cox regression model which included the following clinical and pathological data: age, clinical stage, tumor grade, and residual disease.
RESULTS
Within the PRDXs family, only higher expression of PRDX-5 was associated with worse overall survival both, in unselected patients and > 50-year-olds. PRDX-5 expression and residual disease were independent negative prognostic factors of patient survival.
CONCLUSIONS
PRDX-5 is a negative predictor of survival in ovarian cancer.
目的
过氧化物酶（PRDXs）是一类抗氧化酶家族，也参与致癌过程。它们由六种已确定的亚型（PRDX - 1 - 6）组成，根据癌症类型和PRDX家族成员的不同，在肿瘤进展中可能发挥不同作用。本研究旨在评估PRDXs在卵巢癌中的预后价值。
材料与方法
分析了来自癌症基因组图谱的卵巢癌患者数据集。在260个样本中评估了PRDX - 1至6 mRNA的表达。使用Cox回归模型评估PRDXs的预后价值，该模型纳入了以下临床和病理数据：年龄、临床分期、肿瘤分级和残留病灶。
结果
在PRDXs家族中，只有PRDX - 5的高表达与未筛选患者及年龄>50岁患者的总生存期较差相关。PRDX - 5表达和残留病灶是患者生存的独立负性预后因素。
结论
PRDX - 5是卵巢癌生存的负性预测指标。
Zotero 插件